<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="the viral load. Favipiravir cures all mice in a lethal" exact="influenza infection" post="model, while oseltamivir fails to cure the animals. Thus,"/>
 <result pre="has been used for treatment of human infection with life-threatening" exact="Ebola" post="virus, Lassa virus, rabies, and severe fever with thrombocytopenia"/>
 <result pre="infections for which standard treatments are not available. Keywords Favipiravir" exact="Influenza" post="Antiviral agent Ebola Chain termination Resistant virus Abbreviations baloxavir,"/>
 <result pre="standard treatments are not available. Keywords Favipiravir Influenza Antiviral agent" exact="Ebola" post="Chain termination Resistant virus Abbreviations baloxavir, baloxavir marboxil G-string,"/>
 <result pre="Japan. Favipiravir was highlighted as a treatment during the lethal" exact="Ebola" post="virus epidemic in West Africa in 2014 because a"/>
 <result pre="West Africa in 2014 because a standard treatment for lethal" exact="Ebola" post="virus infection is not available. Favipiravir has been reported"/>
 <result pre="been reported to be effective for prophylaxis and treating lethal" exact="Ebola" post="virus infection in animal models (Oestereich et al., 2014;"/>
 <result pre="used for the post-exposure prophylaxis and treatment of patients with" exact="Ebola" post="virus infection (Bai et al., 2016; Jacobs et al.,"/>
 <result pre="was confirmed by analyzing its efficacy in animal models of" exact="influenza infection," post="as described below, which led to drug development. Favipiravir"/>
 <result pre="infections, as shown in Table 1 . Patients with an" exact="Ebola" post="virus infection in West Africa in 2014 and patients"/>
 <result pre="2008), and gWest Nile fever (Philpott et al., 2019). 2.3" exact="Influenza" post="infection model We have identified two antipyretic steps in"/>
 <result pre="steps in influenza infections, as shown in Fig. 2 ." exact="Influenza" post="infection and its replication in the epithelium of the"/>
 <result pre="by cinnamyl compounds and NSAIDs in the fever cascade in" exact="influenza infection." post="Fig. 2 Cascade of fever induction by influenza and"/>
 <result pre="by influenza and antipyretic action of cinnamyl compounds and NSAIDs." exact="Influenza" post="infection induces interferon (IFN) production that subsequently induces interleukin"/>
 <result pre="of favipiravir were conducted in mice and ferrets using the" exact="influenza infection" post="system described above in our laboratory. 2.4 Efficacy of"/>
 <result pre="favipiravir in influenza-infected animals Since our laboratory had established an" exact="influenza infection" post="model to investigate the cytokine cascade that induces fever"/>
 <result pre="be confirmed. We first observed the prevention of a lethal" exact="influenza infection." post="Oral administration of favipiravir was significantly effective in alleviating"/>
 <result pre="infection. Oral administration of favipiravir was significantly effective in alleviating" exact="influenza infection" post="in mice (Furuta et al., 2002), and its efficacy"/>
 <result pre="oseltamivir was observed in an animal with a severe lethal" exact="influenza infection" post="with a high viral load (Takahashi et al., 2003)."/>
 <result pre="infection model and is considered to correspond to a novel" exact="influenza infection" post="in humans. Although oseltamivir is ineffective in this model,"/>
 <result pre="al., 2019; Wong et al., 2009), respectively, in infected cells." exact="Influenza" post="infection induces TNF-Î± production in mouse macrophage-derived P388D1 cells,"/>
 <result pre="contribute to the enhanced effects of favipiravir treatment on alleviating" exact="influenza infection" post="compared with oseltamivir treatment. Favipiravir displays superior properties to"/>
 <result pre="cycle of influenza and sites of action of anti-influenza drugs." exact="Influenza" post="virus hemagglutinin (HA) binds to its receptor, sialic acid"/>
 <result pre="inoculation of a wild-type A(H1N1) virus (Doyle et al., 1994)." exact="Influenza" post="causes dry cough (90%), fever (83.8%), and headache (82.5%),"/>
 <result pre="Oseltamivir, an NAI, has been the treatment of choice for" exact="influenza infection." post="The emergence of a resistant virus (after day 1)"/>
 <result pre="to an influenza pandemic and spread globally, such as A(H1N1)pdm09." exact="Influenza" post="pandemics can cause severe pneumonia, generate a drug-resistant virus,"/>
 <result pre="has been used to treat humans with diseases such as" exact="Ebola" post="virus infection (Bai et al., 2016; Jacobs et al.,"/>
 <result pre="al., 2016; Jacobs et al., 2015; Sissoko et al., 2016)," exact="Lassa fever" post="(Raabe et al., 2017), norovirus (Ruis et al., 2018),"/>
 <result pre="Furuta et al., 2013; Furuta, Komeno, &amp;amp; Nakamura, 2017). 5.2" exact="Ebola" post="virus infection Concerning Ebola virus infection, the efficacy of"/>
 <result pre="Furuta, Komeno, &amp;amp; Nakamura, 2017). 5.2 Ebola virus infection Concerning" exact="Ebola" post="virus infection, the efficacy of favipiravir in post-exposure prophylaxis"/>
 <result pre="(Smither et al., 2014) and a therapeutic mouse model of" exact="Ebola" post="virus disease (Oestereich, Ludtke, et al., 2014). Treatment with"/>
 <result pre="favipiravir from 6 to 13Â days after lethal infection with" exact="Ebola" post="virus cured all mice when the treatment was started"/>
 <result pre="irreversible levels. Thus, favipiravir may be able to cure an" exact="Ebola" post="virus infection in the early phase of infection, but"/>
 <result pre="dose of favipiravir used to treat a human with an" exact="Ebola" post="virus infection is 6000Â mg on the first day"/>
 <result pre="or favipiravir with other anti-Ebola agents and did not develop" exact="Ebola" post="virus disease (Jacobs et al., 2015). Although the needle"/>
 <result pre="PEP using a mouse model (Smither et al., 2014). An" exact="Ebola" post="study conducted in Guinea included 126 patients, and 111"/>
 <result pre="rate was not statistically significant (Sissoko et al., 2016). An" exact="Ebola" post="study conducted in Sierra Leone included 39 favipiravir-treated patients"/>
 <result pre=".027). (Bai et al., 2016). During the 2014 epidemic of" exact="Ebola" post="virus infection in West Africa, patients who were treated"/>
 <result pre="has been used as an emergency or compassionate treatment for" exact="Lassa fever," post="norovirus, and rabies cases. This review focuses on human"/>
 <result pre="Table 1. Favipiravir has been used in human therapy for" exact="Ebola hemorrhagic fever" post="(Bai et al., 2016, Jacobs et al., 2015; Sissoko"/>
 <result pre="al., 2016, Jacobs et al., 2015; Sissoko et al., 2016)," exact="Lassa fever" post="(Raabe et al., 2017), norovirus (Ruis et al., 2018),"/>
 <result pre="al., 2019). 5.4 The dose of favipiravir for influenza and" exact="Ebola" post="virus infection The antiviral activity (EC50) of favipiravir against"/>
 <result pre="infection The antiviral activity (EC50) of favipiravir against influenza and" exact="Ebola" post="viruses is different from the range of 0.014â€&quot;0.55Â Î¼g/mL"/>
 <result pre="by diffusion from the blood, and in the case of" exact="Ebola" post="virus infection, direct perfusion of blood reaches target tissues,"/>
 <result pre="that promotes polymerase-induced mutation synthesis (Wheeler, Rajagopal, &amp;amp; Mathews, 2005)." exact="Influenza" post="RdRp complex is composed of PB1, PB2, and PA"/>
 <result pre="ATP, GTP, CTP, and UTP, as substrates for RNA synthesis." exact="Influenza" post="RdRp incorporates mismatched nucleotides in a primer-extension-based misincorporation assay"/>
 <result pre="biased nucleotide pool conditions as if the mutagen is present." exact="Influenza" post="RdRp displays a significantly higher fidelity than human immunodeficiency"/>
 <result pre="may be liver failure, renal failure, respiratory failure and encephalitis." exact="Ebola" post="virus infection seemed to be difficult for patients when"/>
 <result pre="2014), indicating the importance of early diagnosis and treatment. In" exact="Ebola" post="virus infection, other than the direct cause of death"/>
 <result pre="compare historical control patients and patients treated with favipiravir for" exact="Ebola" post="virus infection (Bai et al., 2016; Jacobs et al.,"/>
 <result pre="virus replication in vivoElife32014e03679 BaiC.Q.MuJ.S.KargboD.SongY.B.NiuW.K.NieW.M. â€¦JiangJ.F.Clinical and Virological characteristics of" exact="Ebola" post="virus disease patients treated with Favipiravir (T-705)-Sierra Leone, 2014Clinical"/>
 <result pre="TongerenS.A.DongL. â€¦WarrenT.K.Efficacy of favipiravir (T-705) in nonhuman primates infected with" exact="Ebola" post="virus or Marburg virusAntiviral Research15120189710429289666 CaoB.A Pharmacokinetics Study of"/>
 <result pre="genetic analysis of acyclovir-resistant variantsAntiviral Research40199915516610027650 JacobsM.AaronsE.BhaganiS.BuchananR.CropleyI.HopkinsS. â€¦RodgerA.Post-exposure prophylaxis against" exact="Ebola" post="virus disease with experimental antiviral agents: A case-series of"/>
 <result pre="United States of America107201088288720080770 KuA.S.ChanL.T.The first case of H5N1 avian" exact="influenza infection" post="in a human with complications of adult respiratory distress"/>
 <result pre="KurokawaM.ImakitaM.KumedaC.A.YukawaT.A.ShirakiK.Kakkon-to suppressed interleukin 1Î± production responsive to interferon and alleviated" exact="influenza infection" post="in miceJ Traditional Med131996201209 KurokawaM.KumedaC.A.YamamuraJ.KamiyamaT.ShirakiK.Antipyretic activity of cinnamyl derivatives"/>
 <result pre="by Kakkon-to, a herbal medicine, on the early stage of" exact="influenza infection" post="in miceAntiviral Research56200218318812367723 KurokawaM.WatanabeW.ShimizuT.SawamuraR.ShirakiK.Modulation of cytokine production by 7-hydroxycoumarin"/>
 <result pre="cytokine production by 7-hydroxycoumarin in vitro and its efficacy against" exact="influenza infection" post="in miceAntiviral Research85201037338019913056 KurokawaM.YamamuraJ.LiZ.SatoH.HitomiN.TatsumiY.ShirakiK.Antipyretic activity of gingyo-san, a traditional"/>
 <result pre="Europe, 2007-08 seasonEmerging Infectious Diseases15200955256019331731 MemoliM.J.AthotaR.ReedS.CzajkowskiL.BristolT.ProudfootK. â€¦TaubenbergerJ.K.The natural history of" exact="influenza infection" post="in the severely immunocompromised vs nonimmunocompromised hostsClinical Infectious Diseases58201421422424186906"/>
 <result pre="National Kidney FoundationHemodialysis2019National Kidney FoundationNew Yorkhttps://www.kidney.org/atoz/content/hemodialysis OestereichL.LudtkeA.WurrS.RiegerT.Munoz-FontelaC.GuntherS.Successful treatment of advanced" exact="Ebola" post="virus infection with T-705 (favipiravir) in a small animal"/>
 <result pre="Agents and Chemotherapy5720135202520823917318 SchartonD.BaileyK.W.VestZ.WestoverJ.B.KumakiY.Van WettereA. â€¦GowenB.B.Favipiravir (T-705) protects against peracute" exact="Rift Valley fever" post="virus infection and reduces delayed-onset neurologic disease observed with"/>
 <result pre="due to thymidine kinase-deficient/temperature-sensitive virusJournal of Medical Virology7920071731174017854045 ShinyaK.EbinaM.YamadaS.OnoM.KasaiN.KawaokaY.Avian flu:" exact="Influenza" post="virus receptors in the human airwayNature440200643543616554799 ShirakiK.Helicase-primase inhibitor amenamevir"/>
 <result pre="miceAntimicrobial Agents and Chemotherapy51200784585117194832 SissokoD.LaouenanC.FolkessonE.Mâ€™LebingA.B.BeavoguiA.H.BaizeS. â€¦GroupJ.S.Experimental treatment with Favipiravir for" exact="Ebola" post="virus disease (the JIKI trial): A historically controlled, single-arm"/>
 <result pre="therapeuticsPLoS Pathogens92013e1003565 SmitherS.J.EastaughL.S.StewardJ.A.NelsonM.LenkR.P.LeverM.S.Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational" exact="Ebola" post="virus infection in a mouse modelAntiviral Research104201415315524462697 SpicklerA.R.Eastern, Western"/>
</results>
